Loading...

OBIO ORCHESTRA BIOMED HOLDINGS INC US FDA Inspections 8-K Filing

RCHS

B

ORCHESTRA BIOMED HOLDINGS INC

(OBIO)

2025 8-K

Executive Compensation Update

Acquisition Proceeds

Business Update Call

Investor Presentation Update

Termination Agreement

Equity Offerings

Regulatory Compliance

Investigational Device Exem...

Investor Presentation

Executive Compensation Changes

Sales Agreement

Appointment of Director

Annual Meeting Voting Results

Regulation FD Disclosure

Annual Meeting of Stockholders

Agreement Amendment

Regulation FD Disclosure

Registration Statement and ...

FDA Approval for BackBeat C...

Departure of Chief Financia...

Disclosure of Slide Present...

Regulation FD Disclosure

Merger Completed

Meeting Approval

Delisting Notice

General Meeting

External Links:

On April 29, 2025, Orchestra BioMed Holdings announced that the FDA approved an investigational device exemption for their Virtue SAB product trial, aimed at treating coronary artery disease, following a similar announcement on April 22 about a Breakthrough Device Designation for their AVIM therapy for hypertension.

AI Assistant

ORCHESTRA BIOMED HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.